Drug Trial Radar · NCT03995472
A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Feb 14, 2020
Primary completion
Jan 12, 2023
Study completion Jan 12, 2023
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in combination with SHR-1316 in patients with advanced malignancies and to provide a recommended dose (RP2D) for subsequent clinical studies.
Conditions
- Advanced Malignancies
Interventions
SHR-1501Drug
Administered subcutaneously
SHR-1316Drug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity and Maximum tolerated doseTime frame: Approximately 42 Days.
- Recommended Phase 2 dose (RP2D)Time frame: Approximately 2 years
- Adverse event/Serious adverse eventTime frame: Approximately 2 years
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Sydney Southwest Private Hospital
Liverpool, New South Wales, Australia
Scientia Clinical Research
Randwick, New South Wales, Australia
Icon Cancer Centre South Brisbane
South Brisbane, Queensland, Australia
John Flynn Private Hospital
Tugun, Queensland, Australia
Guangdong General Hospital & Guangdong Academy of Medical Sciences
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.